The Inflation Reduction Act’s policy capping out-of-pocket costs for insulin to $35 for a month’s supply led to increases in the total number of insulin fills for Medicare beneficiaries, according to a new study from the USC Schaeffer Center for Health Policy & Economics and University of Wisconsin–Madison.
Latigo, a pain biotech years in the making, emerges with $135M on heels of Vertex PhIII success
On Valentine’s Day, a non-opioid drugmaker unveiled itself after nearly five years of courting drug candidates behind the scenes and working quietly “on the heels” of
February 15, 2024